Literature DB >> 30728335

Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice.

Jonathan S Fletcher1,2, Jianqiang Wu1, Walter J Jessen1,3, Jay Pundavela1, Jacob A Miller1, Eva Dombi4, Mi-Ok Kim5, Tilat A Rizvi1, Kashish Chetal6, Nathan Salomonis6, Nancy Ratner1.   

Abstract

Plexiform neurofibroma is a major contributor to morbidity in patients with neurofibromatosis type I (NF1). Macrophages and mast cells infiltrate neurofibroma, and data from mouse models implicate these leukocytes in neurofibroma development. Antiinflammatory therapy targeting these cell populations has been suggested as a means to prevent neurofibroma development. Here, we compare gene expression in Nf1-mutant nerves, which invariably form neurofibroma, and show disruption of neuron-glial cell interactions and immune cell infiltration to mouse models, which rarely progresses to neurofibroma with or without disruption of neuron-glial cell interactions. We find that the chemokine Cxcl10 is uniquely upregulated in NF1 mice that invariably develop neurofibroma. Global deletion of the CXCL10 receptor Cxcr3 prevented neurofibroma development in these neurofibroma-prone mice, and an anti-Cxcr3 antibody somewhat reduced tumor numbers. Cxcr3 expression localized to T cells and DCs in both inflamed nerves and neurofibromas, and Cxcr3 expression was necessary to sustain elevated macrophage numbers in Nf1-mutant nerves. To our knowledge, these data support a heretofore-unappreciated role for T cells and DCs in neurofibroma initiation.

Entities:  

Keywords:  Cancer; Chemokines; Inflammation; Mouse models; Neuroscience

Year:  2019        PMID: 30728335      PMCID: PMC6413799          DOI: 10.1172/jci.insight.98601

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  72 in total

Review 1.  GTPase activating proteins: critical regulators of intracellular signaling.

Authors:  Shane Donovan; Kevin M Shannon; Gideon Bollag
Journal:  Biochim Biophys Acta       Date:  2002-03-14

2.  Mouse tumor model for neurofibromatosis type 1.

Authors:  K S Vogel; L J Klesse; S Velasco-Miguel; K Meyers; E J Rushing; L F Parada
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

3.  Regulatory proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3.

Authors:  Y Ohba; N Mochizuki; S Yamashita; A M Chan; J W Schrader; S Hattori; K Nagashima; M Matsuda
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

4.  The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.

Authors:  Paul J Hensbergen; Pepijn G J T B Wijnands; Marco W J Schreurs; Rik J Scheper; Rein Willemze; Cornelis P Tensen
Journal:  J Immunother       Date:  2005 Jul-Aug       Impact factor: 4.456

5.  Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts.

Authors:  L S Sherman; R Atit; T Rosenbaum; A D Cox; N Ratner
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

6.  Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis.

Authors:  Benjamin C Ling; Jianqiang Wu; Shyra J Miller; Kelly R Monk; Rania Shamekh; Tilat A Rizvi; Gabrielle Decourten-Myers; Kristine S Vogel; Jeffrey E DeClue; Nancy Ratner
Journal:  Cancer Cell       Date:  2005-01       Impact factor: 31.743

7.  Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development.

Authors:  Antje Rhode; Mary E Pauza; Ana Maria Barral; Evelyn Rodrigo; Michael B A Oldstone; Matthias G von Herrath; Urs Christen
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

8.  Biallelic somatic inactivation of the NF1 gene through chromosomal translocations in a sporadic neurofibroma.

Authors:  Clelia Tiziana Storlazzi; Fredrik Vult Von Steyern; Henryk A Domanski; Nils Mandahl; Fredrik Mertens
Journal:  Int J Cancer       Date:  2005-12-20       Impact factor: 7.396

9.  The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle.

Authors:  Christopher E Brightling; Alaina J Ammit; Davinder Kaur; Judith L Black; Andrew J Wardlaw; J Margaret Hughes; Peter Bradding
Journal:  Am J Respir Crit Care Med       Date:  2005-02-04       Impact factor: 21.405

10.  Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells.

Authors:  Feng-Chun Yang; David A Ingram; Shi Chen; Cynthia M Hingtgen; Nancy Ratner; Kelly R Monk; Travis Clegg; Hilary White; Laura Mead; Mary Jo Wenning; David A Williams; Reuben Kapur; Simon J Atkinson; D Wade Clapp
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

View more
  4 in total

1.  Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.

Authors:  Juan Mo; Ji-Kang Chen; Corina Anastasaki; Jit Chatterjee; Yuan Pan; Suzanne M Scheaffer; Olivia Cobb; Michelle Monje; Lu Q Le; David H Gutmann
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

2.  Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.

Authors:  Daochun Sun; Xuanhua P Xie; Xiyuan Zhang; Zilai Wang; Sameer Farouk Sait; Swathi V Iyer; Yu-Jung Chen; Rebecca Brown; Dan R Laks; Mollie E Chipman; Jack F Shern; Luis F Parada
Journal:  Cell Stem Cell       Date:  2021-05-18       Impact factor: 25.269

3.  P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis.

Authors:  Jennifer Patritti Cram; Jianqiang Wu; Robert A Coover; Tilat A Rizvi; Katherine E Chaney; Ramya Ravindran; Jose A Cancelas; Robert J Spinner; Nancy Ratner
Journal:  Elife       Date:  2022-03-21       Impact factor: 8.140

4.  Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST.

Authors:  Katherine E Chaney; Melissa R Perrino; Leah J Kershner; Ami V Patel; Jianqiang Wu; Kwangmin Choi; Tilat A Rizvi; Eva Dombi; Sara Szabo; David A Largaespada; Nancy Ratner
Journal:  Cancer Res       Date:  2020-08-19       Impact factor: 13.312

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.